Harvard Bioscience (HBIO) Price to Earnings (2010 - 2026)

Harvard Bioscience (HBIO) has reported Price to Earnings for 17 consecutive years, with 9.62 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Price to Earnings fell 12.15% year-over-year to 9.62 in Q2 2026; TTM through Jun 2026 was 32.48, a 9074.3% increase from a year earlier, with the FY2025 full-year figure at 0.66, up 93.46% from the prior year.
• Price to Earnings was 9.62 for Q2 2026 at Harvard Bioscience, down from 6.41 in the prior quarter.
• Over five years, Price to Earnings peaked at 291.92 in Q1 2023 and troughed at 239.14 in Q2 2023.
• A 5-year average of 8.38 and a median of 12.76 in 2025 frame the typical range for Price to Earnings.
• Across the five-year window, Price to Earnings surged 884.21% in 2023 and slumped 1180.19% in 2026, its largest moves.
• Over 5 years, Price to Earnings stood at 194.93 in 2022, then plunged by 165.51% to 127.7 in 2023, then surged by 122.48% to 28.7 in 2024, then slumped by 87.62% to 3.55 in 2025, then tumbled by 370.69% to 9.62 in 2026.
• The last three Price to Earnings figures came in at 9.62 (Q2 2026), 6.41 (Q1 2026), and 3.55 (Q4 2025), per Business Quant data.